Bone health and therapeutic agents in advanced prostate cancer
Prostate cancer is the most frequent genitourinary tumor worldwide. Maintaining an optimum bone health throughout the natural course of prostate cancer is an important aspect in the management of this disease, particularly in this at risk population of older and frail patients who experience bone lo...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
IMR Press
2022-01-01
|
| Series: | Frontiers in Bioscience-Landmark |
| Subjects: | |
| Online Access: | https://www.imrpress.com/journal/FBL/27/1/10.31083/j.fbl2701034 |
| _version_ | 1818355069251223552 |
|---|---|
| author | Maria Antonia Gómez-Aparicio Fernando López-Campos Lira Pelari-Mici David Buchser Jorge Pastor Xavier Maldonado Juan Zafra Alison C. Tree Renée Bultijnck Paul Sargos Piet Ost Felipe Couñago |
| author_facet | Maria Antonia Gómez-Aparicio Fernando López-Campos Lira Pelari-Mici David Buchser Jorge Pastor Xavier Maldonado Juan Zafra Alison C. Tree Renée Bultijnck Paul Sargos Piet Ost Felipe Couñago |
| author_sort | Maria Antonia Gómez-Aparicio |
| collection | DOAJ |
| description | Prostate cancer is the most frequent genitourinary tumor worldwide. Maintaining an optimum bone health throughout the natural course of prostate cancer is an important aspect in the management of this disease, particularly in this at risk population of older and frail patients who experience bone loss related to androgen-deprivation therapy (ADT) and/or patients who develop bone metastases. The number of treatment options for advanced prostate cancer that combine ADT with docetaxel, new hormonal agents and/or radiotherapy has increased substantially in recent years. Bisphosphonates and other bone targeted agents such as denosumab have shown an improvement in bone mineral density and are suited for patients with treatment-related osteoporosis and/or bone metastases with an increased risk of skeletal-related events (SREs). In this context, the aim of this review is to analyse key aspects of bone health and therapies that can prevent the occurrence of SREs throughout the clinical course of prostate cancer, and how to combine them with new available treatments in this setting. |
| first_indexed | 2024-12-13T19:35:27Z |
| format | Article |
| id | doaj.art-814f73e8132b4fdc96673cbfbb7c2734 |
| institution | Directory Open Access Journal |
| issn | 2768-6701 |
| language | English |
| last_indexed | 2024-12-13T19:35:27Z |
| publishDate | 2022-01-01 |
| publisher | IMR Press |
| record_format | Article |
| series | Frontiers in Bioscience-Landmark |
| spelling | doaj.art-814f73e8132b4fdc96673cbfbb7c27342022-12-21T23:33:50ZengIMR PressFrontiers in Bioscience-Landmark2768-67012022-01-0127103410.31083/j.fbl2701034S2768-6701(22)00372-0Bone health and therapeutic agents in advanced prostate cancerMaria Antonia Gómez-Aparicio0Fernando López-Campos1Lira Pelari-Mici2David Buchser3Jorge Pastor4Xavier Maldonado5Juan Zafra6Alison C. Tree7Renée Bultijnck8Paul Sargos9Piet Ost10Felipe Couñago11Department of Radiation Oncology, Hospital Universitario de Toledo, 45007 Toledo, SpainDepartment of Radiation Oncology, Hospital Universitario Ramón y Cajal, 28034 Madrid, SpainDepartment of Radiation Oncology, Hospital Universitario Ramón y Cajal, 28034 Madrid, SpainDepartment of Radiation Oncology, Hospital Universitario Cruces, 48903 Barakaldo, SpainDepartment of Radiation Oncology, ASCIRES Hospital General Universitario de Valencia, 46014 Valencia, SpainDepartment of Radiation Oncology, Hospital Vall d´Hebron, 08035 Barcelona, SpainDepartment of Radiation Oncology, Hospital Universitario Virgen de la Victoria, 29010 Malaga, SpainDepartment of Radiation Oncology, The Royal Marsden Hospital and Institute of Cancer Research, SM2 5PT Sutton, UKDepartment of Radiation Oncology, Ghent University Hospital, 9000 Ghent, BelgiumDepartment of Radiation Oncology, Institut Bergonié, 33000 Bordeaux, FranceDepartment of Radiation Oncology, Iridium Network, 2610 Antwerp, BelgiumDepartment of Radiation Oncology, Hospital Universitario Quironsalud, Hospital La Luz, Universidad Europea de Madrid, 28223 Madrid, SpainProstate cancer is the most frequent genitourinary tumor worldwide. Maintaining an optimum bone health throughout the natural course of prostate cancer is an important aspect in the management of this disease, particularly in this at risk population of older and frail patients who experience bone loss related to androgen-deprivation therapy (ADT) and/or patients who develop bone metastases. The number of treatment options for advanced prostate cancer that combine ADT with docetaxel, new hormonal agents and/or radiotherapy has increased substantially in recent years. Bisphosphonates and other bone targeted agents such as denosumab have shown an improvement in bone mineral density and are suited for patients with treatment-related osteoporosis and/or bone metastases with an increased risk of skeletal-related events (SREs). In this context, the aim of this review is to analyse key aspects of bone health and therapies that can prevent the occurrence of SREs throughout the clinical course of prostate cancer, and how to combine them with new available treatments in this setting.https://www.imrpress.com/journal/FBL/27/1/10.31083/j.fbl2701034bone healthprostate cancerskeletal-related eventsosteoporosisdenosumabbisphosphonates |
| spellingShingle | Maria Antonia Gómez-Aparicio Fernando López-Campos Lira Pelari-Mici David Buchser Jorge Pastor Xavier Maldonado Juan Zafra Alison C. Tree Renée Bultijnck Paul Sargos Piet Ost Felipe Couñago Bone health and therapeutic agents in advanced prostate cancer Frontiers in Bioscience-Landmark bone health prostate cancer skeletal-related events osteoporosis denosumab bisphosphonates |
| title | Bone health and therapeutic agents in advanced prostate cancer |
| title_full | Bone health and therapeutic agents in advanced prostate cancer |
| title_fullStr | Bone health and therapeutic agents in advanced prostate cancer |
| title_full_unstemmed | Bone health and therapeutic agents in advanced prostate cancer |
| title_short | Bone health and therapeutic agents in advanced prostate cancer |
| title_sort | bone health and therapeutic agents in advanced prostate cancer |
| topic | bone health prostate cancer skeletal-related events osteoporosis denosumab bisphosphonates |
| url | https://www.imrpress.com/journal/FBL/27/1/10.31083/j.fbl2701034 |
| work_keys_str_mv | AT mariaantoniagomezaparicio bonehealthandtherapeuticagentsinadvancedprostatecancer AT fernandolopezcampos bonehealthandtherapeuticagentsinadvancedprostatecancer AT lirapelarimici bonehealthandtherapeuticagentsinadvancedprostatecancer AT davidbuchser bonehealthandtherapeuticagentsinadvancedprostatecancer AT jorgepastor bonehealthandtherapeuticagentsinadvancedprostatecancer AT xaviermaldonado bonehealthandtherapeuticagentsinadvancedprostatecancer AT juanzafra bonehealthandtherapeuticagentsinadvancedprostatecancer AT alisonctree bonehealthandtherapeuticagentsinadvancedprostatecancer AT reneebultijnck bonehealthandtherapeuticagentsinadvancedprostatecancer AT paulsargos bonehealthandtherapeuticagentsinadvancedprostatecancer AT pietost bonehealthandtherapeuticagentsinadvancedprostatecancer AT felipecounago bonehealthandtherapeuticagentsinadvancedprostatecancer |